Perrigo Company plc Dossier
Qualitative Analysis
Business overview
Perrigo Company plc is a leading global provider of over-the-counter (OTC) consumer self-care products. Originally founded in 1887, the company has transitioned into a pure-play consumer self-care leader. Perrigo is widely recognized as the largest store brand OTC player in the United States, supplying over half of the U.S. market for store brand OTC products by volume, and ranks as a top 10 OTC company by revenue in Europe. The company operates through a diversified portfolio of self-care products, including upper respiratory, digestive health, pain and sleep aids, healthy lifestyles, and women's health categories. Perrigo's strategic focus centers on its 'Three-S' plan (Stabilize, Streamline, and Strengthen) to drive long-term value.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
A multi-year strategic framework designed to stabilize operations, streamline the product portfolio, and strengthen organizational capabilities. Key actions include shifting to a category-led operating model, divesting non-core assets, and driving market share gains in store brand OTC and key European brands.
Expected impact: Aims to transform Perrigo into a more focused, disciplined, and consistent consumer self-care business with improved operating margins and reduced leverage.
A three-year global investment and efficiency program launched in Q1 2024 to increase organizational agility, reset the SG&A operating expense base, and enable the 'One Perrigo' growth strategy.
Expected impact: Delivered gross annualized pre-tax savings of approximately $167 million as of the end of FY2025, towards the high end of the estimated $140 million to $170 million range, with $35 million reinvested.
A new two-year enterprise-wide operational enhancement program launched in early 2026 to further streamline operations and enhance organizational effectiveness.
Expected impact: Targeting $80 million to $100 million in annualized run-rate cost savings, with approximately 80% of the savings expected to be realized in 2026.
An initiative launched in 2022 to reduce structural costs, improve profitability and service levels to retail partners, and streamline the global supply chain.
Expected impact: Achieved approximately $157 million in annualized benefits by the end of fiscal year 2025, supporting a global service level of 94%.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Collaborative partnership to offer co-branded infant formula solutions (Good Start and Dr. Brown's), leveraging brand equity to support recovery in the infant nutrition segment.
Terms: Not disclosed